STOCK TITAN
  1. Home
  2. Sec-filings
  3. OLMA
  4. [Form 4] Olema Pharmaceuticals, Inc. Insider Trading Activity

Olema Pharmaceuticals (OLMA) officer sells shares after option exercises

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Olema Pharmaceuticals executive David C. Myles reported multiple stock option exercises and share sales. On January 13 and 14, he exercised a total of 100,000 stock options at an exercise price of $4.87 per share, resulting in 50,000 stock options remaining outstanding. Over January 13–14, he sold 100,000 shares of common stock in the market at weighted average prices ranging from $27.60 to $28.99 per share, leaving 542,761 shares held directly.

An entity associated with him, Myles Properties Inc., sold 10,000 shares on January 12 at a weighted average price of $28.34, and continued to hold 144,846 shares indirectly. A family trust associated with him held an additional 12,831 shares indirectly. The filing also notes that a prior Form 4 overstated his directly owned shares by 120 shares due to a scrivener's error, which is corrected here.

Positive

  • None.

Negative

  • None.
Insider Myles David C.
Role CH. DISCOV. & NON-CLIN DEV OFF
Sold 110,000 shs ($3.11M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 50,000 $0.00 --
Exercise Common Stock 50,000 $4.87 $244K
Sale Common Stock 14,997 $28.60 $429K
Sale Common Stock 35,003 $28.99 $1.01M
Exercise Stock Option (Right to Buy) 50,000 $0.00 --
Exercise Common Stock 50,000 $4.87 $244K
Sale Common Stock 49,800 $27.60 $1.37M
Sale Common Stock 200 $28.49 $6K
Sale Common Stock 10,000 $28.34 $283K
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 50,000 shares (Direct); Common Stock — 592,761 shares (Direct); Common Stock — 144,846 shares (Indirect, See Footnote)
Footnotes (1)
  1. The weighted average sale price for the transaction reported was $28.34, and the range of prices were between $28.07 and $28.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. The shares are held by Myles Properties Inc., of which the Reporting Person is President. On December 23, 2025, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be overstated by 120 shares. That error has been corrected in this Form 4. The weighted average purchase price for the transaction reported was $27.60, and the range of prices were between $27.35 and $28.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. The weighted average sale price for the transaction reported was $28.60, and the range of prices was between $27.80 and $28.79. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $28.99, and the range of prices was between $28.80 and $29.39. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee. 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Myles David C.
(Last) (First) (Middle)
C/O OLEMA PHARMACEUTICALS, INC.
780 BRANNAN ST
(Street)
SAN FRANCISCO CA 94103
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CH. DISCOV. & NON-CLIN DEV OFF
3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/12/2026 S 10,000 D $28.34(1) 144,846 I See Footnote(2)
Common Stock 01/13/2026 M 50,000 A $4.87 592,761(3) D
Common Stock 01/13/2026 S 49,800 D $27.6(4) 542,961 D
Common Stock 01/13/2026 S 200 D $28.49 542,761 D
Common Stock 01/14/2026 M 50,000 A $4.87 592,761 D
Common Stock 01/14/2026 S 14,997 D $28.6(5) 577,764 D
Common Stock 01/14/2026 S 35,003 D $28.99(6) 542,761 D
Common Stock 12,831 I See Footnote(7)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $4.87 01/13/2026 M 50,000 (8) 01/31/2033 Common Stock 50,000 $0 100,000 D
Stock Option (Right to Buy) $4.87 01/14/2026 M 50,000 (9) 01/31/2033 Common Stock 50,000 $0 50,000 D
Explanation of Responses:
1. The weighted average sale price for the transaction reported was $28.34, and the range of prices were between $28.07 and $28.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
2. The shares are held by Myles Properties Inc., of which the Reporting Person is President.
3. On December 23, 2025, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be overstated by 120 shares. That error has been corrected in this Form 4.
4. The weighted average purchase price for the transaction reported was $27.60, and the range of prices were between $27.35 and $28.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.
5. The weighted average sale price for the transaction reported was $28.60, and the range of prices was between $27.80 and $28.79. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
6. The weighted average sale price for the transaction reported was $28.99, and the range of prices was between $28.80 and $29.39. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
7. The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.
8. 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
9. 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
/s/ Shane Kovacs, Attorney-in-Fact 01/14/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Olema Pharmaceuticals (OLMA) report in this Form 4?

The filing shows David C. Myles exercised 100,000 stock options at $4.87 per share on January 13 and 14 and sold 100,000 shares of Olema common stock over those two days at prices between $27.60 and $28.99 per share.

How many Olema (OLMA) shares does David C. Myles own after these transactions?

After the reported transactions, David C. Myles held 542,761 Olema common shares directly, 144,846 shares indirectly through Myles Properties Inc., and 12,831 shares indirectly through The Myles Family Revocable Inter Vivos Trust.

What stock options did the Olema (OLMA) executive exercise in this Form 4?

He exercised two tranches of stock options, each for 50,000 shares of Olema common stock, on January 13 and January 14 at an exercise price of $4.87 per share, leaving 50,000 stock options beneficially owned following the transactions.

What pricing details are disclosed for the Olema (OLMA) share sales?

Sales on January 12 had a weighted average price of $28.34 with a range of $28.07–$28.66. January 13 sales included a weighted average purchase price of $27.60 with a range of $27.35–$28.21, while January 14 sales had weighted average prices of $28.60 and $28.99 with disclosed price ranges.

Did this Olema (OLMA) Form 4 correct any prior reporting errors?

Yes. The filing notes that a Form 4 filed on December 23, 2025 contained a scrivener's error that overstated the number of shares beneficially owned directly by David C. Myles by 120 shares, and that this Form 4 corrects that error.